Adashek, Jacob J. http://orcid.org/0000-0003-4272-312X
Pandya, Chinmayi
Maragakis, Nicholas J.
De, Pradip
Cohen, Philip R.
Kato, Shumei
Kurzrock, Razelle
Funding for this research was provided by:
Division of Cancer Prevention, National Cancer Institute (5U01CA180888-08, 5UG1CA233198-05)
Article History
Received: 2 November 2023
Accepted: 12 February 2024
First Online: 19 February 2024
Declarations
:
: Consent was obtained from the patient presented in this manuscript.
: Consent was obtained from the patient presented in this manuscript.
: Jacob J. Adashek serves on the advisory board of CureMatch Inc. and serves as a consultant for datma. Chinmayi Pandya has no conflicts of interest. Nicholas J. Maragakis serves as a consultant and/or advisory boards of Amylyx; Cytokinetics; Healey Center; Nura Bio, Northeast ALS Consortium; Akava. He receives research/grant support from Apellis Pharma; Biogen Idec; Cytokinetics; Roche; Helixmith; Calico; Sanofi; Department of Defense ALSRP; Maryland Stem Cell Research Fund; Massachusetts General Hospital; Medicinova; NINDS. Pradip De is a paid consultant of Viecure. Philip R. Cohen is a consultant for ParaPRO. Shumei Kato serves as a consultant for Foundation Medicine. He receives speaker’s fee from Roche and advisory board for Pfizer. He has research funding from ACT Genomics, Sysmex, Konica Minolta, and OmniSeq. Razelle Kurzrock has received research funding from Biological Dynamics, Boehringer Ingelheim, Debiopharm, Foundation Medicine, Genentech, Grifols, Guardant,Incyte, Konica Minolta, Medimmune, Merck Serono, Omniseq, Pfizer, Sequenom, Takeda, and TopAlliance; as well as consultant and/or speaker fees and/or advisory board for Actuate Therapeutics, AstraZeneca, Bicara Therapeutics, Biological Dynamics, Caris, Daiichi Sankyo, Inc., Datar Cancer Genetics, EISAI, EOM Pharmaceuticals, Iylon, LabCorp, Merck, NeoGenomics, Neomed, Pfizer, Prosperdtx, Roche, TD2/Volastra, Turning Point Therapeutics, X-Biotech; has an equity interest in CureMatch Inc., CureMetrix, and IDbyDNA; serves on the Board of CureMatch and CureMetrix; and is a co-founder of CureMatch.